Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alzamend Neuro, Inc

0.9507
+0.01081.15%
Post-market: 0.9489-0.0018-0.19%16:35 EDT
Volume:188.82K
Turnover:180.67K
Market Cap:6.27M
PE:-0.23
High:1.01
Open:0.9700
Low:0.9006
Close:0.9399
Loading ...

Alzamend Neuro Inc : Ascendiant Capital Markets Cuts Target Price to $35 From $50

THOMSON REUTERS
·
11 Nov 2024

Alzamend Neuro Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
11 Nov 2024

BRIEF-Alzamend Neuro Announces Full Data Set From Phase Iia Multiple Ascending Dose Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer’S

Reuters
·
16 Oct 2024

Alzamend Neuro Inc - Identified Dose Unlikely to Require Lithium Therapeutic Drug Monitoring

THOMSON REUTERS
·
16 Oct 2024

Alzamend Neuro Inc - to Initiate Five Clinical Trials Based on Study Results

THOMSON REUTERS
·
16 Oct 2024

Alzamend Neuro Announces Full Data Set From Phase Iia Multiple Ascending Dose Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’s

THOMSON REUTERS
·
16 Oct 2024

Alzamend Neuro Inc - Maximum Tolerated Dose for Al001 Confirmed at 240 Mg Tid

THOMSON REUTERS
·
16 Oct 2024

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Business Wire
·
16 Oct 2024

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's

Benzinga
·
16 Oct 2024

Alzamend Neuro Regains Nasdaq Compliance After Strategic Appeal

TIPRANKS
·
16 Oct 2024

Alzamend Neuro Regains Nasdaq Compliance Over Listing Requirements

MT Newswires Live
·
15 Oct 2024

Alzamend Neuro regains compliance with Nasdaq isting standards

TIPRANKS
·
15 Oct 2024

BRIEF-Alzamend Neuro Regains Compliance With Nasdaq Listing Standards

Reuters
·
15 Oct 2024

Alzamend Neuro Regains Compliance With Nasdaq Listing Standards

THOMSON REUTERS
·
15 Oct 2024

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Business Wire
·
15 Oct 2024

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

Business Wire
·
10 Oct 2024